ISHA Therapeutics Receives U.S. FDA QIDP Designation for ISHA-004 for the Treatment of Oropharyngeal Candidiasis
HILLSBOROUGH TOWNSHIP, NJ, UNITED STATES, April 27, 2026 /EINPresswire.com/ -- ISHA Therapeutics LLC, a company focused on advancing therapies through the 505(b)(2) regulatory pathway, today announced that the U.S. Food and Drug Administration ( …